Leadership & Pay ·
Optimi Health Corp. appointed Dr. Michael Blough as its new Chief Clinical Development Officer on September 22, 2026
OPTHOptimi Health Corp.
Optimi Health Corp. appointed Dr. Michael Blough as its new Chief Clinical Development Officer on September 22, 2026. In this newly created role, Dr. Blough will oversee the company's clinical development strategy and operations for its planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD. The appointment supports protocol execution, site activation, and Health Canada interactions as both trials are expected to begin enrolling patients next year. Optimi Health Corp. is a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products for mental health therapies.